Block Listing Six Monthly Return
Source: RNS
|
For immediate release |
29 December 2022 |
ALLIANCE PHARMA PLC
("Alliance" or the "Company")
Block Listing Six Monthly Return
|
Name of applicant: |
ALLIANCE PHARMA PLC |
|||
|
Names of schemes: |
a) The Alliance Pharma plc Approved Share Option Plan 2005 b) The Alliance Pharma plc Share Option Plan 2006 c) The Alliance Pharma plc Company Share Option Plan 2015 d) The Alliance Pharma plc Long-Term Incentive Plan 2019 |
|||
|
Period of return: |
From: |
28 June 2022 |
To: |
28 December 2022 |
|
Number of securities originally admitted at date of admission: |
25,000,000 ordinary shares of 1p each 28 June 2017 |
|||
|
Balance of unallotted securities under schemes from previous return: |
a) 161,946 b) 2,551,168 c) 9,654,020 d) 1,500,000 |
|||
|
Plus: The amount by which the block schemes have been increased since the date of the last return (if any increase has been applied for): |
a) Nil b) Nil c) Nil d) Nil |
|||
|
Less: Number of securities issued/allotted under schemes during period: |
a) 12,309 b) 0 c) 81,398 d) 158,884
|
|||
|
Equals: Balance under schemes not yet issued/allotted at end of period: |
e) 149,637 f) 2,551,168 g) 9,572,622 h) 1,341,116 |
|||
|
Name of contact: |
Chris Chrysanthou, Company Secretary |
|
Telephone number of contact: |
Tel. +44 (0)1249 705166 |
For further information:
|
Alliance Pharma plc |
+ 44 (0)1249 466966 |
|
Cora McCallum, Head of Investor Relations & Corporate Communications |
+ 44 (0)1249 705168 |
|
|
|
|
|
|
|
Buchanan |
+ 44 (0)20 7466 5000 |
|
Mark Court / Hannah Ratcliff |
|
|
|
|
|
|
|
|
Numis Securities Limited |
+ 44 (0)20 7260 1000 |
|
Nominated Adviser: Freddie Barnfield / Duncan Monteith |
|
|
Corporate Broking: James Black |
|
|
|
|
|
Investec Bank plc |
+ 44 (0)20 7597 5970 |
|
Corporate Finance: Daniel Adams |
|
|
Corporate Broking: Patrick Robb |
|
About Alliance
Alliance Pharma plc (AIM: APH) is an international healthcare group. Our purpose is to improve the lives of consumers and patients through making available a range of clinically valuable healthcare products.
Our core focus is on the marketing of Consumer Healthcare brands, complemented by a smaller Prescription Medicines business. In total, we hold marketing rights to around 80 brands, with revenues generated from a mix of direct, distributor and e-commerce sales.
Headquartered in the UK, Alliance employs around 250 people based in locations across Europe, North America, and the Asia Pacific region. By outsourcing our manufacturing and logistics operations, we remain asset-light and focused on maximising the value of our brands.
For more information on Alliance, please visit our website: www.alliancepharmaceuticals.com
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
